Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and has an increasing incidence worldwide, accounting for 20% of all cholangiocarcinomas.1,2 Characterized by high invasiveness and frequent postoperative recurrence, ICC exhibits one of the highest mortality rates among human cancers.1,3 Despite recent progress in understanding ICC pathogenesis and novel therapies with specific targets, such as IDH1 variance4 and FGFR2 fusion,5 ICC is still incurable in most cases.6,7,8,9. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.